Tsao Anne S, Mehran Reza, Roth Jack A
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Clin Lung Cancer. 2009 Jan;10(1):36-41. doi: 10.3816/CLC.2009.n.005.
Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of neoadjuvant chemotherapy with platinum doublets and most recently novel targeted agents, such as dasatinib. Intrapleural strategies have included injecting chemotherapy, chemotherapy with hyper thermic per fusion, gene therapy, and immunotherapy. The following review discusses the latest results in neoadjuvant and intrapleural therapies in malignant pleural mesothelioma.
从历史上看，患有潜在可切除疾病的恶性胸膜间皮瘤患者一直仅接受手术和放疗。随着全身和胸膜内治疗选择的改善，多模式治疗的趋势变得更加普遍。全身治疗选择主要包括铂类双联新辅助化疗以及最近的新型靶向药物，如达沙替尼。胸膜内治疗策略包括注射化疗、热灌注化疗、基因治疗和免疫治疗。以下综述讨论了恶性胸膜间皮瘤新辅助治疗和胸膜内治疗的最新结果。
